An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2015
Price : $35 *
At a glance
- Drugs Denosumab (Primary) ; Pamidronic acid
- Indications Bone cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Amgen
- 17 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record.
- 09 Jun 2014 Planned initiation date changed from 1 May 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 12 May 2014 Planned initiation date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.